✦ LIBER ✦

Safety and tolerability of rosiglitazone XR in a randomised, placebo-controlled study in APOE4-stratified subjects with mild-to-moderate Alzheimer's disease

✍ Scribed by Marina Zvartau-Hind; Claire Alderton; Sally Ritchie; Ann Saunders; Michael Irizarry; Suzanne Craft; Gary Landreth; Ülla Linnamägi; Sharon Sawchak; Michael Gold

Book ID: 118464882
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 169 KB
Volume: 5
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2009.04.252

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Secondary endpoint and responder analyse

Secondary endpoint and responder analyses in a study of rosiglitazone XR in APOE4-stratified subjects with mild-to-moderate Alzheimer's disease

✍ Alderton, Claire; Zvartau-Hind, Marina; Ritchie, Sally; Saunders, Ann; Craft, Su 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Effects of rosiglitazone as monotherapy

Effects of rosiglitazone as monotherapy in APOE4-stratified subjects with mild-to-moderate Alzheimer's disease

✍ Michael Gold; Claire Alderton; Marina Zvartau-Hind; Sally Ritchie; Ann Saunders; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 125 KB

Effects Of Rosiglitazone-extended Releas

Effects Of Rosiglitazone-extended Release As Adjunctive Therapy To Acetylcholinesterase Inhibitors Over 48 Weeks On Cognition In Apoe4-stratified Subjects With Mild-to-moderate Alzheimer'S Disease

✍ Harrington, Conn; Sawchak, Sharon; Chiang, Carl; Davies, John; Saunders, Ann; Ir 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 237 KB

Safety and tolerability of BMS-708163 in

Safety and tolerability of BMS-708163 in a phase II study in mild-to-moderate Alzheimer's disease

✍ Salloway, Stephen; Coric, Vlad; Brody, Mark; Andreasen, Niels; van Dyck, Christo 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 82 KB

A long-term, double-blind, placebo-contr

A long-term, double-blind, placebo-controlled efficacy and safety study of nicergoline in patients with mild to moderate Alzheimer's disease

✍ L. Amaducci; K. Maurer; B. Winblad; R. Dom; R. Bullock; L. Bonura; A. Battaglia; 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 291 KB

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre